Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts.

ABSTRACT: Antiangiogenic therapy with bevacizumab has shown varying results in breast cancer clinical trials. Identifying robust biomarkers for selecting patients who may benefit from such treatment and for monitoring response is important for the future use of bevacizumab. Two established xenograft models representing basal-like and luminal-like breast cancer were used to study bevacizumab treatment response on the metabolic and gene expression levels. Tumor samples were obtained from mice treated with bevacizumab, doxorubicin or a combination of the two drugs, and high resolution magic angle spinning magnetic resonance spectroscopy and gene expression microarray analysis was performed. Combination treatment with bevacizumab showed the strongest growth inhibiting effect in basal-like tumors, and th

SUBMITTER: Borgan E 

PROVIDER: S-EPMC5528408 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature